2,5-二氯苯基缩水甘油基醚 | 21324-87-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-二氯苯基缩水甘油基醚
• 英文名称: 1-(2,5-dichloro-phenoxy)-2,3-epoxypropane
• 英文别名: 1-(2,5-dichlorophenoxy)-2,3-epoxypropane；(2,5-dichloro-phenoxymethyl)-oxirane；1-(2,5-dichloro)-phenoxy-2,3-epoxypropane；2,5-dichlorophenyl glycidyl ether；1<2,5-Dichlorphenoxy>-2,3-epoxypropan；2-[(2,5-Dichlorophenoxy)methyl]oxirane
• CAS: 21324-87-8
• 化学式: C₉H₈Cl₂O₂
• mdl: MFCD06655043
• 分子量: 219.067
• InChiKey: BKYYOPSMOZNITO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,5-二氯苯基缩水甘油基醚 在 水 、 乙酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以95%的产率得到(RS)-1-chloro-3-(2,5-dichlorophenoxy)propan-2-ol
  参考文献：
  名称：

  探索荧光假单胞菌脂肪酶在消旋中间体动力学拆分中的快速潜力及其通过分子对接的验证。

  摘要：

  对于（合成的深刻时间有效的化学酶促方法小号）- 3-（4-氯苯氧基）丙-1,2-二醇和（小号）- 1-氯-3-（2,5-二氯苯氧基）丙-2-使用荧光假单胞菌成功开发了两种重要的药物中间体-ol脂肪酶（PFL）。使用乙酸乙烯酯作为酰化剂，甲苯/己烷作为溶剂，反应温度为30°C，成功实现了动力学拆分，从而实现了高对映选择性和转化率。在最佳条件下，PFL表现出50.2％的转化率，95.0％的对映体过量，在1小时的最佳时间内对映选择性（E = 153）和50.3％的转化率，95.2％的对映体过量，在最佳时间内的对映选择性（E = 161）两种外消旋醇分别需要3小时。所述的对接R-和小号证实羟基的之间更强的氢键相互作用的中间体的对映异构体[R -对映体和键结合脂肪酶的催化位点的残基，而小号对映体的相互作用较小。因此，对接研究补充了PFL优先酰化中间体R形式的实验结果。本研究证明了一种经济有效的快速生

  DOI：

  10.1002/chir.22771
• 作为产物：
  描述：

  2,5-二氯苯酚 以89%的产率得到
  参考文献：
  名称：

  BERCHER H.; EHLERS D.; GRISK A., PHARMAZIE , 1976, 31, NO 6, 351-354;

  摘要：

  DOI：

文献信息

• Studies on Agents with Vasodilator and ,B-Blocking Activities. IV.
  作者：Toshimi SEKI、Tomio NAKAO、Takeshi MASUDA、Kohichi HASUMI、Kotaro GOTANDA、Tsutomu ISHIMORI、Seijiro HONMA、Nobuyoshi MINAMI、Kenyu SHIBATA、Kikuo YASUDA

  DOI：10.1248/cpb.44.2061

  日期：——

  A series of novel pyridazinone derivatives (II) having a phenoxypropanolamine moiety was synthesized. Their hypotensive and β-blocking activities were evaluated after intravenous administration of the compounds to anesthetized rats. Among them, the 5-chloro-2-cyanophenoxy derivative (29) showed the promising dual activities and was selected for further studies.

  合成了一系列具有苯氧基丙醇胺结构的新型哒嗪酮衍生物（II）。在静脉注射给麻醉大鼠后，评估了它们的降压和β-阻断活性。其中，5-氯-2-氰基苯氧基衍生物（29）显示出有前途的双重活性，并被选中进行进一步研究。
• Studies on Agents with Vasodilator and .BETA.-Blocking Activities. II.
  作者：Toshimi SEKI、Takayuki TAKEZAKI、Rikio OHUCHI、Hiroshi OHUYABU、Yoshitaka TANIMOTO、Takashi YAMAGUCHI、Norinobu SAITOH、Tsutomu ISHIMORI、Kikuo YASUDA

  DOI：10.1248/cpb.43.247

  日期：——

  A series of phenoxypropanolamines having a hydrazinopyridazinyl moiety was synthesized. Their hypotensive and β-blocking activities were evaluated after intravenous administration of the compounds to anethetized rats.Some of them exhibited both activities. In particular, compound 20k is a candidate for clinical use due to its hypotensive activity, equal to that of hydralazine, and its β-blocking activity, 2.7-fold more potent than that of propranolol.

  一系列含有哒嗪基肼结构的苯氧丙醇胺类化合物被合成，并通过静脉注射给麻醉大鼠后评估了它们的降压和β阻断活性。其中一些化合物显示了这两种活性。特别是化合物20k，由于其降压活性与肼达嗪相当，且β阻断活性比普萘洛尔强2.7倍，因此被认为是临床应用的候选药物。
• Antihypertensive pyridazinone aminoisopropanol derivatives
  申请人：Teikoku Hormone Mfg. Co., Ltd.

  公开号：US04843072A1

  公开（公告）日：1989-06-27

  A pyridazinone derivative represented by the following general formula ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group, either one of R.sub.2, R.sub.3 and R.sub.4 represents a hydrogen atom and the remaining two of them represent a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and a salt thereof. The compounds are useful as antihypertensive agents.

  以下是该化合物的中文翻译：一种由下列一般式所代表的吡啶并酮衍生物，其中R.sub.1代表氢原子或甲基基团，R.sub.2、R.sub.3和R.sub.4中的任一种代表氢原子，其余两种代表较低的烷基基团、三氟甲基基团、卤原子、氰基或硝基，以及其盐。这些化合物可用作降压药。
• Cardioactive pyrazole and imidazole aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04608383A1

  公开（公告）日：1986-08-26

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamide, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, notro, hydraxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, halomethyl, aminomethyl, lower acylaminomethyl, di(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acyaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. These compounds are useful for the prophylaxis and combatting of cardiac and circulatory diseases.

  本发明提供了通式为：##STR1##的芳基氧代丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢或卤素原子或较低的烷基、氰基、羧酰胺、羟基、较低的酰氧基、较低的烷氧基、较低的烯基氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰胺基、较低的烷基氨基、二(较低烷基)氨基、羟乙基氨基、二(羟乙基)氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧酰胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰氨基甲基、卤甲基、氨基甲基、较低的酰氨基甲基、二(较低烷基)-氨基甲基、吡咯烷甲基、哌啶甲基、二(羟乙基)-氨基甲基、吡咯啉甲基、哌嗪甲基、4-较低的酰基哌嗪甲基、4-较低的烷基哌嗪甲基、较低的烷基、较低的烯基、2-氰基乙基、2-羟基乙基、苯基较低的烷基和苯基等单价或二价取代基，其中苯基基团可以选择性地取代1或2个羟基或甲氧基基团，或者从氧或硫；其光学活性形式和外消旋混合物，以及其药理兼容盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。这些化合物对于预防和治疗心脏和循环疾病非常有用。
• Cardioactive aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04438128A1

  公开（公告）日：1984-03-20

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamido, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, nitro, hydroxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-(lower alkoxycarbonyl)-ethyl, 2-carboxyethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

  本发明提供了通式为：##STR1##的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢原子或卤素原子或较低的烷基、氰基、羧胺基、羟基、较低的酰氧基、较低的烷氧基、较低的烯氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但前提是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰氨基、较低的烷基氨基、二(较低的烷基)-氨基、羟乙基氨基、二(羟乙基)-氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰胺基甲基、二(较低的烷基)-胺基甲基、吡咯烷基甲基、哌啶基甲基、二(羟乙基)-胺基甲基、吗啉基甲基、哌嗪基甲基、4-较低的酰基哌嗪基甲基、4-较低的烷基哌嗪基甲基、较低的烷基、较低的烯基、2-氰基乙基、2-(较低的烷氧羰基)-乙基、2-羧基乙基、2-羟基乙基、苯基较低的烷基和苯基中的苯基，苯基基团可以选择性地用1或2个羟基或甲氧基基团取代，或者用氧或硫替代；其光学活性形式和其外消旋混合物，以及其药理相容的盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。